Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Tadalafil | hsa00190 | Oxidative phosphorylation | 1.07E-02 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Tadalafil | hsa00520 | Amino sugar and nucleotide sugar metabolism | 1.59E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Tadalafil | hsa00524 | Neomycin, kanamycin and gentamicin biosynthesis | 2.03E-02 | 1 | P35557 | GCK | More | | Tadalafil | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Tadalafil | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Tadalafil | hsa00600 | Sphingolipid metabolism | 2.44E-02 | 2 | Q9BX95, Q06136 | SGPP1, FVT1 | More | | Tadalafil | hsa00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 7.10E-03 | 2 | P06865, O75752 | HEXA, B3GALNT1 | More | | Tadalafil | hsa00730 | Thiamine metabolism | 1.15E-03 | 2 | Q9Y6K8, P24666 | AK5, ACP1 | More | | Tadalafil | hsa00740 | Riboflavin metabolism | 4.03E-02 | 1 | P24666 | ACP1 | More | | Tadalafil | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Tadalafil | hsa00785 | Lipoic acid metabolism | 4.32E-02 | 1 | Q9Y234 | LIPT1 | More | | Tadalafil | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | | Tadalafil | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Tadalafil | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Tadalafil | hsa03040 | Spliceosome | 2.09E-02 | 7 | Q14562, O43143, O75940, O75494, Q07955, Q01130, Q13243 | DHX8, DHX15, SMNDC1, FUSIP1, SFRS1, SFRS2, SFRS5 | More | | Tadalafil | hsa03050 | Proteasome | 2.26E-02 | 2 | P55036, P28074 | PSMD4, PSMB5 | More | | Tadalafil | hsa03450 | Non-homologous end-joining | 3.17E-03 | 2 | Q9NP87, P13010 | POLM, XRCC5 | More | | Tadalafil | hsa04014 | Ras signaling pathway | 1.70E-02 | 7 | P20827, Q9NRA1, P49767, P17252, P0DP23, P62873, P19174 | EFNA1, PDGFC, VEGFC, PRKCA, CALM1, GNB1, PLCG1 | More | | Tadalafil | hsa04015 | Rap1 signaling pathway | 4.58E-02 | 6 | P20827, Q9NRA1, P49767, P0DP23, P17252, P19174 | EFNA1, PDGFC, VEGFC, CALM1, PRKCA, PLCG1 | More | | Tadalafil | hsa04020 | Calcium signaling pathway | 2.01E-02 | 6 | P17252, P19174, P0DP23, P20020, Q9NRA1, P49767 | PRKCA, PLCG1, CALM1, ATP2B1, PDGFC, VEGFC | More | | Tadalafil | hsa04070 | Phosphatidylinositol signaling system | 4.40E-02 | 4 | P19174, P0DP23, P23743, P17252 | PLCG1, CALM1, DGKA, PRKCA | More | | Tadalafil | hsa04114 | Oocyte meiosis | 1.35E-02 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Tadalafil | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Tadalafil | hsa04144 | Endocytosis | 4.10E-02 | 3 | O75351, P62491, Q14161 | VPS4B, RAB11A, GIT2 | More | | Tadalafil | hsa04145 | Phagosome | 4.68E-02 | 5 | Q15080, P14598, Q13509, P68371, Q13488 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1 | More | | Tadalafil | hsa04217 | Necroptosis | 7.22E-05 | 13 | P01375, P01568, P48023, Q13489, Q13546, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, RIPK1, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP2A, PPID | More | | Tadalafil | hsa04360 | Axon guidance | 2.29E-02 | 5 | P16333, P20827, O95631, P17252, P19174 | NCK1, EFNA1, NTN1, PRKCA, PLCG1 | More | | Tadalafil | hsa04370 | VEGF signaling pathway | 9.69E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Tadalafil | hsa04390 | Hippo signaling pathway | 5.79E-03 | 4 | P04628, Q9UJU2, O43623, Q13489 | WNT1, LEF1, SNAI2, BIRC3 | More | | Tadalafil | hsa04512 | ECM-receptor interaction | 2.93E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | | Tadalafil | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Tadalafil | hsa04540 | Gap junction | 1.67E-02 | 4 | P17252, Q13509, P68371, Q9NRA1 | PRKCA, TUBB3, TUBB2C, PDGFC | More | | Tadalafil | hsa04610 | Complement and coagulation cascades | 3.52E-02 | 2 | P09871, P20023 | C1S, CR2 | More | | Tadalafil | hsa04611 | Platelet activation | 5.13E-04 | 4 | P08514, Q15746, Q8WYR1, P07359 | ITGA2B, MYLK, PIK3R5, GP1BA | More | | Tadalafil | hsa04612 | Antigen processing and presentation | 4.78E-02 | 6 | P48382, P26715, P26717, Q13241, O43908, P01375 | RFX5, KLRC1, KLRC2, KLRD1, KLRC4, TNF | More | | Tadalafil | hsa04613 | Neutrophil extracellular trap formation | 9.78E-04 | 8 | P16109, Q99878, Q93077, P62807, O60814, P68431, P08514, P07359 | SELP, H2AC14, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, ITGA2B, GP1BA | More | | Tadalafil | hsa04621 | NOD-like receptor signaling pathway | 2.27E-02 | 9 | Q9H1Y0, P43490, O00463, Q05823, P01375, P49913, P59665, P59666, P12838 | ATG5, PBEF1, TRAF5, RNASEL, TNF, CAMP, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | Tadalafil | hsa04623 | Cytosolic DNA-sensing pathway | 4.28E-04 | 3 | P01568, Q13546, P25963 | IFNA21, RIPK1, NFKBIA | More | | Tadalafil | hsa04640 | Hematopoietic cell lineage | 2.62E-02 | 3 | P07359, P08514, P20023 | GP1BA, ITGA2B, CR2 | More | | Tadalafil | hsa04650 | Natural killer cell mediated cytotoxicity | 1.25E-02 | 8 | P01375, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | TNF, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Tadalafil | hsa04657 | IL-17 signaling pathway | 2.97E-02 | 5 | P25963, P08238, Q07955, P04141, P06702 | NFKBIA, HSP90AB1, SFRS1, CSF2, S100A9 | More | | Tadalafil | hsa04660 | T cell receptor signaling pathway | 3.80E-02 | 6 | P04141, P25963, P10747, P19174, P16333, P29350 | CSF2, NFKBIA, CD28, PLCG1, NCK1, PTPN6 | More | | Tadalafil | hsa04662 | B cell receptor signaling pathway | 4.53E-03 | 3 | P20023, Q8WV28, P11912 | CR2, BLNK, CD79A | More | | Tadalafil | hsa04713 | Circadian entrainment | 3.32E-02 | 4 | P0DP23, P17252, P62873, O15055 | CALM1, PRKCA, GNB1, PER2 | More | | Tadalafil | hsa04720 | Long-term potentiation | 4.54E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Tadalafil | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Tadalafil | hsa04744 | Phototransduction | 1.18E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Tadalafil | hsa04914 | Progesterone-mediated oocyte maturation | 1.88E-02 | 4 | Q17RY0, Q9Y6D9, P51812, Q02750 | CPEB4, MAD1L1, RPS6KA3, MAP2K1 | More | | Tadalafil | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | | Tadalafil | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.72E-02 | 5 | P42224, Q12778, P49767, P17252, P19174 | STAT1, FOXO1, VEGFC, PRKCA, PLCG1 | More | | Tadalafil | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Tadalafil | hsa04950 | Maturity onset diabetes of the young | 2.03E-02 | 1 | P35557 | GCK | More | | Tadalafil | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | | Tadalafil | hsa05012 | Parkinson disease | 3.12E-02 | 6 | Q16718, O14521, P19174, P0DP23, Q13509, P68371 | NDUFA5, SDHD, PLCG1, CALM1, TUBB3, TUBB2C | More | | Tadalafil | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | | Tadalafil | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.29E-02 | 9 | Q13509, P68371, Q16718, O14521, Q13561, P19174, P17252, Q08752, P0DP23 | TUBB3, TUBB2C, NDUFA5, SDHD, DCTN2, PLCG1, PRKCA, PPID, CALM1 | More | | Tadalafil | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Tadalafil | hsa05100 | Bacterial invasion of epithelial cells | 4.54E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | | Tadalafil | hsa05110 | Vibrio cholerae infection | 1.98E-02 | 3 | Q13488, P17252, P19174 | TCIRG1, PRKCA, PLCG1 | More | | Tadalafil | hsa05131 | Shigellosis | 2.93E-02 | 6 | Q9NQL2, P0CG47, Q14141, Q96JJ3, Q05397, Q13315 | RRAGD, UBB, SEPT6, ELMO2, PTK2, ATM | More | | Tadalafil | hsa05132 | Salmonella infection | 1.91E-04 | 11 | P25963, P08238, Q9UJU2, Q13546, Q13489, P04406, O75369, Q13561, Q13509, P68371, P49754 | NFKBIA, HSP90AB1, LEF1, RIPK1, BIRC3, GAPDH, FLNB, DCTN2, TUBB3, TUBB2C, VPS41 | More | | Tadalafil | hsa05140 | Leishmaniasis | 1.72E-02 | 5 | P14598, P42224, P25963, P29350, Q15080 | NCF1, STAT1, NFKBIA, PTPN6, NCF4 | More | | Tadalafil | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Tadalafil | hsa05144 | Malaria | 3.12E-02 | 4 | P60033, P01375, P35443, P26718 | CD81, TNF, THBS4, KLRK1 | More | | Tadalafil | hsa05150 | Staphylococcus aureus infection | 2.03E-04 | 9 | P09871, P21730, P21462, O75015, P16109, P59665, P59666, P12838, P49913 | C1S, C5AR1, FPR1, FCGR3B, SELP, DEFA1; DEFA1B, DEFA3, DEFA4, CAMP | More | | Tadalafil | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Tadalafil | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 5.71E-03 | 8 | P01568, P42224, P25963, P40189, P62873, P19174, P04141, P0DP23 | IFNA21, STAT1, NFKBIA, IL6ST, GNB1, PLCG1, CSF2, CALM1 | More | | Tadalafil | hsa05168 | Herpes simplex virus 1 infection | 4.15E-03 | 12 | P25963, P01568, Q9GZY0, P42224, Q07955, Q01130, Q13243, Q13398, Q03923, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, NXF2; NXF2B, STAT1, SFRS1, SFRS2, SFRS5, ZNF211, ZNF85, ZNF140, ZNF189, ZNF212 | More | | Tadalafil | hsa05170 | Human immunodeficiency virus 1 infection | 3.80E-02 | 5 | Q02750, P62879, P16298, Q05397, Q13315 | MAP2K1, GNB2, PPP3CB, PTK2, ATM | More | | Tadalafil | hsa05171 | Coronavirus disease - COVID-19 | 1.36E-02 | 7 | P25963, P42224, P01568, P40189, P04141, P19174, P17252 | NFKBIA, STAT1, IFNA21, IL6ST, CSF2, PLCG1, PRKCA | More | | Tadalafil | hsa05200 | Pathways in cancer | 1.75E-02 | 14 | P08238, P42224, P25963, P19174, P17252, P43246, P14923, P49767, Q12778, P62873, O75293, P0DP23, P01568, P40189 | HSP90AB1, STAT1, NFKBIA, PLCG1, PRKCA, MSH2, JUP, VEGFC, FOXO1, GNB1, GADD45B, CALM1, IFNA21, IL6ST | More | | Tadalafil | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Tadalafil | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Tadalafil | hsa05214 | Glioma | 1.09E-02 | 4 | P0DP23, P17252, P19174, O75293 | CALM1, PRKCA, PLCG1, GADD45B | More | | Tadalafil | hsa05217 | Basal cell carcinoma | 4.31E-02 | 2 | P04628, Q9UJU2 | WNT1, LEF1 | More | | Tadalafil | hsa05231 | Choline metabolism in cancer | 2.25E-03 | 5 | Q9NRA1, Q9Y259, P19174, P23743, P17252 | PDGFC, CHKB, PLCG1, DGKA, PRKCA | More | | Tadalafil | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.97E-02 | 5 | P25963, P19174, P29350, P42224, P10747 | NFKBIA, PLCG1, PTPN6, STAT1, CD28 | More | | Tadalafil | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Tadalafil | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Tadalafil | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Tadalafil | hsa05340 | Primary immunodeficiency | 2.93E-02 | 2 | P11912, Q8WV28 | CD79A, BLNK | More | | Tadalafil | hsa05415 | Diabetic cardiomyopathy | 1.20E-02 | 6 | P17252, P14598, Q15080, Q16718, O14521, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, GAPDH | More | | |